0.9398
1.69%
-0.0162
전일 마감가:
$0.956
열려 있는:
$0.94
하루 거래량:
64,167
Relative Volume:
0.37
시가총액:
$73.48M
수익:
-
순이익/손실:
$-20.59M
주가수익비율:
-2.807
EPS:
-0.3348
순현금흐름:
$-17.99M
1주 성능:
+1.05%
1개월 성능:
-1.89%
6개월 성능:
-4.97%
1년 성능:
-56.29%
Oncolytics Biotech Inc Stock (ONCY) Company Profile
Oncolytics Biotech Inc Stock (ONCY) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2022-10-06 | 개시 | Maxim Group | Buy |
2021-02-17 | 개시 | H.C. Wainwright | Buy |
Oncolytics Biotech Inc 주식(ONCY)의 최신 뉴스
Oncolytics Biotech Engages Investors at Key Conferences - TipRanks
Oncolytics Biotech Inc - Baystreet.ca
Oncolytics Biotech® to Participate in Fireside Chats at Two Investment Conferences in September - IT News Online
Oncolytics Biotech® to Participate in Fireside Chats at Two Investment Conferences in September - Quantisnow
Oncolytic Virus Therapy Market to See Booming Growth 2024-2031 | - openPR
Oncolytics Biotech® to Participate in Fireside Chats at Two Investment Conferences in September - Barchart
Oncolytics Biotech Inc. Forecasted to Earn FY2024 Earnings of ($0.29) Per Share (NASDAQ:ONCY) - MarketBeat
HC Wainwright Weighs in on Oncolytics Biotech Inc.'s FY2024 Earnings (TSE:ONC) - MarketBeat
HC Wainwright Analysts Decrease Earnings Estimates for Oncolytics Biotech Inc. (NASDAQ:ONCY) - Defense World
Oncolytics Biotech (NASDAQ:ONCY) Receives "Buy" Rating from HC Wainwright - MarketBeat
Oncolytics Biotech (NASDAQ:ONCY) Earns “Buy” Rating from HC Wainwright - Defense World
Thinking about buying stock in Oncolytics Biotech, Nikola Corp, Joby Aviation, Ideanomics, or Better Therapeutics? - GuruFocus.com
Oncolytics Biotech® to Host Conference Call to Discuss Second Qu - GuruFocus.com
Oncolytics Biotech® Receives Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX +/- an anti-PD-L1 Inhibitor in Pancreatic Cancer - Longview News-Journal
Oncolytics Biotech’s Pelareorep Shows Promise in Metastatic Breast Cancer Treatment - Vancity Buzz
Stock Surge: Oncolytics Biotech, Inc. (ONCY) Closes at 0.91, Marking a -4.06 Increase/Decrease - The Dwinnex
Extending Survival: Oncolytics Biotech's Pelareorep Shows Promise In Fighting Metastatic Breast Cancer - Nasdaq
Biotech Innovations Poised to Transform Pancreatic Cancer Treatment and Patient Outcomes - Baystreet.ca
Biotech Innovations: Revolutionary Treatments Aim to Boost Pancreatic Cancer Survival Rates - Barchart
Biotech Innovations: Revolutionary Treatments Aim to Boost Pancreatic Cancer Survival Rates - Quantisnow
Advancements In Cancer Therapeutics: What To Expect From The Upcoming 2024 Oncology Conference - MENAFN.COM
Biotech Innovations Drive Pancreatic Cancer Treatment: Market Expected To Reach $7.4 Billion By 2032 - MENAFN.COM
Virtu Financial LLC Acquires New Stake in Oncolytics Biotech Inc. (NASDAQ:ONCY) - Defense World
Oncolytic Virus Therapy Market Expected to Expand at a Steady - openPR
ONCY:UN - BNN Bloomberg
Oncolytics Biotech Announces Equity Distribution Deal - TipRanks
Earnings call: Oncolytics Biotech outlines progress in cancer trials By Investing.com - Investing.com Australia
Earnings call: Oncolytics Biotech outlines progress in cancer trials By Investing.com - Investing.com UK
Oncolytics Biotech Inc (ONCY) Q2 2024 Earnings Call Transcript H - GuruFocus.com
Oncolytics Biotech® to Participate in a Fireside Chat at Canaccord Genuity's 44th Annual Growth Conference - The Malaysian Reserve
Oncolytics Biotech® to Participate in a Fireside Chat at Canaccord Genuity's 44th Annual Growth Conference - StreetInsider.com
Oncolytics Biotech® to Participate in a Fireside Chat at Canaccord Genuity's 44th Annual Growth Conference - BioSpace
Oncolytics Biotech (TSE:ONC) Stock Passes Above Two Hundred Day Moving Average of $1.47 - Defense World
Oncolytics Biotech® to Participate in a Fireside Chat at Canaccord Genuity's 44th Annual Growth Conference - Financial Times
Oncolytics Biotech (TSE:ONC) Share Price Crosses Above Two Hundred Day Moving Average of $1.47 - MarketBeat
Q2 2024 Oncolytics Biotech Inc Earnings Call Transcript - GuruFocus.com
Earnings call: Oncolytics Biotech outlines progress in cancer trials By Investing.com - Investing.com Canada
Oncolytics Biotech Inc. (ONCY) Q2 2024 Earnings Call Transcript - Seeking Alpha
Oncolytics Biotech’s Financials Show Asset Decline - TipRanks
Oncolytics Biotech Advances Cancer Trials with Solid Funding - TipRanks
Oncolytics Biotech® Reports Second Quarter 2024 Financial Results and Operational Highlights - PR Newswire
Oncolytics Biotech® to Participate in a Fireside Chat at the 2024 RBC Capital Markets Global Healthcare Conference - Kilgore News Herald
Pancreatic Cancer Poised to Become Second Leading Cause of Cancer Death; New Treatment Shows Promise - Vancity Buzz
Pancreatic Cancer Could Overtake Colorectal Cancer To Become Second Leading Cause Of Cancer Death – Oncolytics Is Working On A Promising Treatment - Nasdaq
Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders - Kilgore News Herald
Pancreatic Cancer Could Overtake Colorectal Cancer To Become Second Leading Cause Of Cancer Death – Oncolytics Is Working On A Promising Treatment - News Channel Nebraska
Oncolytics Biotech (ONCY) Set to Announce Quarterly Earnings on Thursday - MarketBeat
Oncolytics Biotech (ONC) Set to Announce Earnings on Thursday - MarketBeat
Here's Why We're Watching Oncolytics Biotech's (TSE:ONC) Cash Burn Situation - Yahoo Finance
Oncolytics Biotech Inc. - Baystreet.ca
Stocks In Play: Oncolytics Biotech Inc. - Barchart
Oncolytics Biotech Inc (ONCY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):